Liaoning Cheng Da Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Liaoning Cheng Da heeft een totaal eigen vermogen van CN¥32.1B en een totale schuld van CN¥15.2B, wat de schuld-eigenvermogensverhouding op 47.2% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥48.5B en CN¥16.4B.

Belangrijke informatie

47.2%

Verhouding schuld/eigen vermogen

CN¥15.16b

Schuld

Rente dekkingsratio	n/a
Contant	CN¥7.71b
Aandelen	CN¥32.14b
Totaal verplichtingen	CN¥16.36b
Totaal activa	CN¥48.51b

Recente financiële gezondheidsupdates

Is Liaoning Cheng Da (SHSE:600739) A Risky Investment?

Sep 25

Here's Why Liaoning Cheng Da (SHSE:600739) Can Afford Some Debt

Jun 04

Recent updates

There May Be Some Bright Spots In Liaoning Cheng Da's (SHSE:600739) Earnings

Nov 11

Returns On Capital At Liaoning Cheng Da (SHSE:600739) Paint A Concerning Picture

Oct 18

Liaoning Cheng Da Co., Ltd.'s (SHSE:600739) 35% Share Price Surge Not Quite Adding Up

Sep 27

Is Liaoning Cheng Da (SHSE:600739) A Risky Investment?

Sep 25

Investor Optimism Abounds Liaoning Cheng Da Co., Ltd. (SHSE:600739) But Growth Is Lacking

Jul 01

Liaoning Cheng Da Co., Ltd.'s (SHSE:600739) Earnings Are Not Doing Enough For Some Investors

Mar 05

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥12.0B ) 600739 } overtreffen de korte termijn passiva ( CN¥11.3B ).

Langlopende schulden: De kortetermijnactiva 600739 ( CN¥12.0B ) overtreffen de langetermijnschulden ( CN¥5.1B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 23.2% ) 600739 wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 600739 is de afgelopen 5 jaar gedaald van 52.9% naar 47.2%.

Schuldendekking: De schuld van 600739 wordt niet goed gedekt door de operationele kasstroom ( 3% ).

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van 600739 op haar schulden goed worden gedekt door EBIT.

Liaoning Cheng Da Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Liaoning Cheng Da (SHSE:600739) A Risky Investment?

Here's Why Liaoning Cheng Da (SHSE:600739) Can Afford Some Debt

Recent updates

There May Be Some Bright Spots In Liaoning Cheng Da's (SHSE:600739) Earnings

Returns On Capital At Liaoning Cheng Da (SHSE:600739) Paint A Concerning Picture

Liaoning Cheng Da Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Liaoning Cheng Da Co., Ltd.'s (SHSE:600739) 35% Share Price Surge Not Quite Adding Up

Investor sentiment improves as stock rises 20%

Is Liaoning Cheng Da (SHSE:600739) A Risky Investment?

Second quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.13 in 2Q 2023)

Investor Optimism Abounds Liaoning Cheng Da Co., Ltd. (SHSE:600739) But Growth Is Lacking

Liaoning Cheng Da Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Here's Why Liaoning Cheng Da (SHSE:600739) Can Afford Some Debt

Liaoning Cheng Da Co., Ltd., Annual General Meeting, Jun 21, 2024

Some May Be Optimistic About Liaoning Cheng Da's (SHSE:600739) Earnings

Full year 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.80 in FY 2022)

Liaoning Cheng Da (SHSE:600739) Has Some Way To Go To Become A Multi-Bagger

Liaoning Cheng Da Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Liaoning Cheng Da Co., Ltd.'s (SHSE:600739) Earnings Are Not Doing Enough For Some Investors

Investor sentiment improves as stock rises 21%

Liaoning Cheng Da Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

New major risk - Financial data availability

Third quarter 2023 earnings released: EPS: CN¥0.067 (vs CN¥0.16 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.43 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥0.80 (vs CN¥1.41 in FY 2021)

Now 20% undervalued after recent price drop

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.34 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.53 in 2Q 2021)

Liaoning Cheng Da Co., Ltd. (SHSE:600739) announces an Equity Buyback for CNY 200 million worth of its shares, under the authorization approved on May 31, 2022.

Full year 2021 earnings released: EPS: CN¥1.41 (vs CN¥1.81 in FY 2020)

Less than half of directors are independent

Liaoning Cheng Da Co., Ltd.(XSSC:600739) dropped from FTSE All-World Index (USD)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.53 (vs CN¥0.53 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.35 (vs CN¥0.093 in 1Q 2020)

Third quarter 2020 earnings released: EPS CN¥1.03

Liaoning Cheng Da Co., Ltd. to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low: CN¥23.28

First half earnings released

New 90-day high - CN¥31.35

Sinopharm Holding GuoDa Drug Store Co., Ltd. completed the acquisition of Chengda Fangyuan Pharmaceutical Group Co., Ltd. from Liaoning Cheng Da Co., Ltd. (SHSE:600739).

Sinopharm Holding GuoDa Drug Store Co., Ltd. entered into an agreement to acquire Chengda Fangyuan Pharmaceutical Group Co., Ltd. from Liaoning Cheng Da Co., Ltd. (SHSE:600739) for CNY 1.9 billion.

Liaoning Cheng Da Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven